AC Immune SA (ACIU) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed AC Immune SA (ACIU) over the past year, losing 6.4% versus a loss of 27.6%. Over five years, LFCR leads with a -34.5% price change compared with -58.7% for ACIU. AC Immune SA is the larger company by market cap ($253.5 million vs $243.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | LFCR |
|---|---|---|
| Share price | $2.55 | $6.43 |
| Market cap | $253.54M | $243.73M |
| 1-day change | -0.78% | -0.16% |
| YTD return | -18.79% | -21.39% |
| 1-year return | -27.56% | -6.40% |
| 5-year return | -58.74% | -34.45% |
| Forward P/E | 4.29 | — |
| EPS (TTM) | $-0.54 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $8.98 |
| 52-week low | $2.10 | $3.63 |
| Distance from 52-week high | -36.25% | -28.40% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +234.12% | -2.33% |
| Average volume | 201.86K | 294.61K |
| Shares outstanding | 99.43M | 37.91M |
| Employees | 90 | 382 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed ACIU by 21.2 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
ACIU vs LFCR FAQ
Which is bigger, AC Immune SA or Lifecore Biomedical?
AC Immune SA (ACIU) is larger, with a market capitalization of $253.54M compared with $243.73M for Lifecore Biomedical (LFCR).
Which stock has performed better over the past year, ACIU or LFCR?
LFCR returned -6.40% over the past 12 months, compared with -27.56% for ACIU (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Lifecore Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.